- Home
- TSHA vs SMBC Comparison
TSHA vs SMBC Comparison
Compare TSHA & SMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- SMBC
- Stock Information
- Founded
- TSHA 2019
- SMBC 1887
- Country
- TSHA United States
- SMBC United States
- Employees
- TSHA N/A
- SMBC N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- SMBC Banks
- Sector
- TSHA Health Care
- SMBC Finance
- Exchange
- TSHA Nasdaq
- SMBC Nasdaq
- Market Cap
- TSHA 728.4M
- SMBC 587.7M
- IPO Year
- TSHA 2020
- SMBC N/A
- Fundamental
- Price
- TSHA $2.65
- SMBC $56.85
- Analyst Decision
- TSHA Strong Buy
- SMBC Buy
- Analyst Count
- TSHA 6
- SMBC 3
- Target Price
- TSHA $8.17
- SMBC $64.67
- AVG Volume (30 Days)
- TSHA 2.6M
- SMBC 63.6K
- Earning Date
- TSHA 08-11-2025
- SMBC 07-23-2025
- Dividend Yield
- TSHA N/A
- SMBC 1.62%
- EPS Growth
- TSHA N/A
- SMBC 8.53
- EPS
- TSHA N/A
- SMBC 4.99
- Revenue
- TSHA $7,224,000.00
- SMBC $172,928,000.00
- Revenue This Year
- TSHA N/A
- SMBC $15.25
- Revenue Next Year
- TSHA N/A
- SMBC $6.17
- P/E Ratio
- TSHA N/A
- SMBC $11.39
- Revenue Growth
- TSHA N/A
- SMBC 6.00
- 52 Week Low
- TSHA $1.05
- SMBC $45.10
- 52 Week High
- TSHA $3.31
- SMBC $68.69
- Technical
- Relative Strength Index (RSI)
- TSHA 56.06
- SMBC 55.91
- Support Level
- TSHA $2.34
- SMBC $55.25
- Resistance Level
- TSHA $2.81
- SMBC $57.75
- Average True Range (ATR)
- TSHA 0.16
- SMBC 1.63
- MACD
- TSHA 0.01
- SMBC -0.09
- Stochastic Oscillator
- TSHA 67.37
- SMBC 56.07
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About SMBC Southern Missouri Bancorp Inc.
Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.